CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 118 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $12,447,000 | +113.0% | 1,719,247 | +2.7% | 0.23% | +112.0% |
| Q2 2020 | $5,844,000 | +43.6% | 1,674,447 | -39.1% | 0.11% | -5.3% |
| Q1 2020 | $4,071,000 | -26.2% | 2,750,616 | -2.2% | 0.11% | -13.6% |
| Q4 2019 | $5,515,000 | -65.4% | 2,813,565 | -9.7% | 0.13% | -75.3% |
| Q3 2019 | $15,953,000 | -29.0% | 3,115,865 | -0.7% | 0.53% | -16.0% |
| Q2 2019 | $22,471,000 | -42.5% | 3,138,365 | +6.6% | 0.64% | -44.4% |
| Q1 2019 | $39,093,000 | +68.4% | 2,943,765 | -0.2% | 1.14% | +22.6% |
| Q4 2018 | $23,208,000 | -30.0% | 2,948,865 | -1.5% | 0.93% | -8.5% |
| Q3 2018 | $33,169,000 | -16.4% | 2,993,565 | +1.2% | 1.02% | -24.3% |
| Q2 2018 | $39,693,000 | +3.4% | 2,957,765 | +0.1% | 1.35% | -9.1% |
| Q1 2018 | $38,393,000 | +108.4% | 2,955,565 | +47.6% | 1.48% | +85.1% |
| Q4 2017 | $18,421,000 | +38.8% | 2,002,265 | +21.6% | 0.80% | +22.3% |
| Q3 2017 | $13,276,000 | – | 1,647,100 | – | 0.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,254,502 | $20,741,000 | 14.54% |
| Versant Venture Management, LLC | 1,048,601 | $9,647,127,000 | 10.15% |
| Abingworth LLP | 1,147,077 | $10,553,000 | 7.65% |
| Omega Fund Management, LLC | 551,477 | $5,074,000 | 3.67% |
| Opaleye Management Inc. | 665,000 | $6,118,000 | 1.96% |
| DAFNA Capital Management LLC | 361,164 | $3,323,000 | 1.79% |
| Boxer Capital, LLC | 1,012,986 | $9,319,000 | 1.70% |
| Foresite Capital Management III, LLC | 600,000 | $5,520,000 | 1.55% |
| NEXTHERA CAPITAL LP | 536,568 | $4,936,000 | 0.91% |
| Perceptive Advisors | 2,685,882 | $24,710,000 | 0.82% |